A study by the University of Cincinnati has identified variations in pancreatic tumors which might explain why the disease impacts some patients differently. This could lead to more personalized treatment approaches for pancreatic cancer.
Researchers analyzed 22 pancreatic tumors from patients with differing racial backgrounds across the United States, focusing on differences in cancer cells and the immune system’s response. The study examined seven Black patients and 15 non-African American patients. These findings were published in the journal Cancer Research.
The tumors from Black patients presented fewer typical pancreatic cancer cells and a higher number of cells displaying a mix of different characteristics. Some of these characteristics have been linked to drug resistance, though the study did not determine whether they influence treatment outcomes.
Additionally, tumors from Black patients contained more B cells, a specific type of immune cell, and larger clusters of these immune cells. Researchers observed indications that some B cells might suppress the body’s response to cancer, but the importance of these differences remains uncertain.
Dr. Raymond Wadlow, a gastrointestinal medical oncologist at the Inova Schar Cancer Institute in Virginia, mentioned the difficulty of using immunotherapy in treating pancreatic cancer. According to him, the pancreatic tumor manipulates the immune system, causing it to fight against the patient’s body instead of the disease.
The study did not find major genetic differences between the racial groups that are known to influence the disease’s development. Pancreatic cancer is reportedly 20% more prevalent in Black Americans than in non-African Americans.
“Ignoring diverse ancestry in medical research leaves blind spots in the search for a cure,” said lead author Dr. Nina Steele, an assistant professor at UC’s College of Medicine.
Dr. Wadlow pointed out that while significant DNA mutations are shared, the behavior and interaction of cancer cells with immune cells and surrounding tissues vary greatly. He highlighted that these differences might also vary across diverse patient populations.
Pancreatic cancer can show variation even within the same tumor, showing the complexity involved. The presence of immune cells and surrounding tissues can significantly influence how a tumor behaves, possibly explaining why uniform treatment methods do not work for everyone.
The research findings carry several limitations. It remains unestablished how the intermediate tumor cells impact survival or respond to chemotherapy, said Steele. Future studies should include pancreatic tissue from healthy individuals to discover when these differences emerge.
Dr. Wadlow stressed that race and genetic ancestry alone do not entirely explain the environmental, socioeconomic, and biological factors influencing these findings. Larger studies with diverse participants are necessary to determine whether these differences affect treatment outcomes or survival rates.
It is important for newly diagnosed patients to inquire about hereditary genetic testing, which aids in identifying mutations that can be inherited by relatives.
Steele emphasized the need for inclusive clinical trials reflecting the diverse patient population affected by pancreatic cancer. This is essential to develop treatments accessible to all affected patients.
The National Cancer Institute partially funded the research.
